TEVA

NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Dollar change -0.59
Percentage change -3.38	%

Peers: VTRS PRGO AMRX GSK BMY PFE MRK NVS ABBV JNJ

| Held by: IEFA EFA EFV PPH IXUS EIS SPDW IDEV IVLU FNDF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.14	Insider Own	0.25%	Shs Outstand	1.15B	Perf Week	-4.03%
Market Cap	19.35B	Forward P/E	6.14	EPS next Y	2.75	Insider Trans	-31.69%	Shs Float	1.14B	Perf Month	24.19%
Income	-1286.00M	PEG	-	EPS next Q	0.65	Inst Own	62.71%	Short Float	2.49%	Perf Quarter	3.37%
Sales	16.56B	P/S	1.17	EPS this Y	2.43%	Inst Trans	6.72%	Short Ratio	2.22	Perf Half Y	-1.29%
Book/sh	5.46	P/B	3.09	EPS next Y	7.76%	ROA	-3.17%	Short Interest	28.43M	Perf Year	3.94%
Cash/sh	1.48	P/C	11.40	EPS next 5Y	7.13%	ROE	-18.98%	52W Range	12.47 - 22.80	Perf YTD	-23.37%
Dividend Est.	-	P/FCF	9.29	EPS past 5Y	-9.62%	ROI	-5.65%	52W High	-25.92%	Beta	0.61
Dividend TTM	-	Quick Ratio	0.74	Sales past 5Y	-0.32%	Gross Margin	49.01%	52W Low	35.50%	ATR (14)	0.80
Dividend Ex-Date	Nov 27, 2017	Current Ratio	1.03	EPS Y/Y TTM	-175.90%	Oper. Margin	20.40%	RSI (14)	57.14	Volatility	5.66% 4.09%
Employees	36167	Debt/Eq	2.71	Sales Y/Y TTM	3.38%	Profit Margin	-7.76%	Recom	1.60	Target Price	23.67
Option/Short	Yes / Yes	LT Debt/Eq	2.64	EPS Q/Q	249.11%	Payout	-	Rel Volume	0.89	Prev Close	17.48
Sales Surprise	-2.44%	EPS Surprise	12.43%	Sales Q/Q	0.84%	Earnings	May 07 BMO	Avg Volume	12.79M	Price	16.89
SMA20	7.71%	SMA50	9.67%	SMA200	-3.68%	Trades		Volume	11,465,815	Change	-3.38%

Date	Action	Analyst	Rating Change	Price Target Change
May-12-25	Upgrade	JP Morgan	Neutral → Overweight	$23
Jul-10-24	Upgrade	Argus	Hold → Buy	$20
Mar-08-24	Upgrade	JP Morgan	Underweight → Neutral	$14
Feb-12-24	Upgrade	Piper Sandler	Neutral → Overweight	$12 → $19
Jan-23-24	Upgrade	Jefferies	Hold → Buy	$10 → $14
Jan-03-24	Upgrade	Piper Sandler	Underweight → Neutral	$8 → $12
Dec-18-23	Initiated	HSBC Securities	Buy	$13
Nov-27-23	Upgrade	UBS	Neutral → Buy	$11 → $13
Jul-06-23	Upgrade	UBS	Sell → Neutral	$7 → $8
May-25-23	Initiated	Morgan Stanley	Equal-Weight	$10
May-18-23	Upgrade	Evercore ISI	In-line → Outperform
Jan-19-23	Downgrade	Jefferies	Buy → Hold	$10 → $12
Nov-14-22	Downgrade	JP Morgan	Neutral → Underweight	$11 → $10
Nov-04-22	Downgrade	UBS	Neutral → Sell
Oct-21-22	Resumed	Jefferies	Buy	$10
Aug-05-22	Upgrade	BofA Securities	Neutral → Buy	$10 → $13
Jun-14-22	Resumed	UBS	Neutral	$10
May-17-22	Upgrade	BofA Securities	Underperform → Neutral	$9
May-04-22	Downgrade	Piper Sandler	Neutral → Underweight	$11 → $7
Apr-05-22	Upgrade	Barclays	Equal Weight → Overweight	$11 → $13

Show Previous Ratings

May-14-25 07:41AM	Teva Pharmaceutical Industries Limited (TEVA): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying (Insider Monkey)
May-12-25 05:02PM	Why Teva Pharmaceuticals Stock Blasted 6% Higher Today (Motley Fool) +6.08%
04:14PM	Teva's Bold $700M Gamble: Will It Be Enough to Rescue Its Plummeting Stock? (GuruFocus.com)
07:00AM	Teva's 2024 Healthy Future Report Highlights Sustainability Progress, Including Surpassed Targets Linked to Financial Strategy (GlobeNewswire)
May-09-25 05:09PM	Analyst Report: Teva Pharmaceutical Industries Limited (Morningstar Research) -6.31%
04:21AM	Loading…
04:21AM	Teva Pharmaceutical Industries Limited (TEVA): Among Billionaire Larry Robbins' Stock Picks with Huge Upside Potential (Insider Monkey)
May-08-25 11:12AM	Analyst Report: Teva Pharmaceutical Industries Limited (Morningstar Research)
07:48AM	TEVA Beats on Q1 Earnings, Expects $700M Cost Savings by 2027, Stock Up (Zacks)
03:06AM	Teva Pharmaceutical Industries Ltd (TEVA) Q1 2025 Earnings Call Highlights: Strong Growth in ... (GuruFocus.com)
01:48AM	Why Teva Pharmaceutical Industries Limited (TEVA) Skyrocketed On Wednesday (Insider Monkey)
May-07-25 04:16PM	Teva Stock Jumps On Outlook. CEO Touts 'Real Clarity' On Future Profits. (Investor's Business Daily) +9.18%
02:08PM	Why Teva Pharmaceutical Stock Is Soaring Today (Motley Fool)
01:01PM	Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says (Barrons.com)
10:49AM	Teva targets $2.5B sales for Austedo in 2027 while advancing innovative portfolio (Seeking Alpha)
10:47AM	Teva Pharmaceutical Industries Limited (TEVA) Q1 2025 Earnings Call Transcript (Seeking Alpha)
09:30AM	Loading…
09:30AM	Teva Pharmaceutical Industries (TEVA) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
08:47AM	Teva Surges On Profit Guidance Boost Despite A Mixed First-Quarter Report (Investor's Business Daily)
08:47AM	Teva Jumps As Profit Beats, Guidance Hike Outweighs Light Sales (Investor's Business Daily)
08:00AM	Teva rises as forex impact drives Q1 revenue miss (Seeking Alpha)
07:30AM	Teva Pharmaceutical's branded drugs boost first quarter profit (Reuters)
07:00AM	Teva to Host Innovation & Strategy Day on Thursday, May 29 in New York City (GlobeNewswire)
07:00AM	Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved (GlobeNewswire)
May-06-25 02:50PM	Q1 2025 Corcept Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
05:49AM	FDA approves Selarsdi injection as interchangeable with Stelara (Pharmaceutical Technology)
May-05-25 09:50AM	Teva Pharmaceutical Industries Ltd. (TEVA) is a Top-Ranked Momentum Stock: Should You Buy? (Zacks)
09:15AM	What Analyst Projections for Key Metrics Reveal About Teva Pharmaceutical Industries (TEVA) Q1 Earnings (Zacks)
07:49AM	Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI (ustekinumab-aekn) with Stelara (ustekinumab) (GlobeNewswire)
May-02-25 01:18PM	FOLD Q1 Earnings and Sales Miss Estimates, Stock Falls (Zacks)
Apr-28-25 09:40AM	Why This 1 Value Stock Could Be a Great Addition to Your Portfolio (Zacks)
Apr-27-25 11:40PM	Why AbbVie's Stock Is A Strong Buy After Q1 2025 Results (Seeking Alpha)
08:29PM	Loading…
Apr-24-25 08:29PM	Analyst Report: Teva Pharmaceutical Industries Limited (Morningstar Research)
07:46AM	Johnson & Johnson Just Proved The Bears Wrong Again (Seeking Alpha)
Apr-21-25 08:21AM	Should You Buy, Sell or Hold AstraZeneca Stock Before Q1 Earnings? (Zacks)
03:51AM	Trump Tariff Sell-Off: 3 Superb Stocks That Make for No-Brainer Buys Right Now (Motley Fool)
Apr-17-25 08:03AM	Here's How You Should Play JNJ Stock After Q1 Earnings Beat (Zacks)
Apr-16-25 04:38AM	Zacks Industry Outlook Dr. Reddy's, Sandoz and Teva Pharmaceuticals (Zacks)
Apr-15-25 11:14AM	JNJ Tops Q1 Earnings, Ups '25 Sales View to Include Intra-Cellular Deal (Zacks)
07:15AM	3 Generic Drug Stocks to Watch Amid Trade War Jitters & Inflation Woes (Zacks)
Apr-13-25 03:06AM	5 of the Safest Stocks Billionaire Money Managers Bought Ahead of Wall Street's Historic Volatility (Motley Fool)
Apr-11-25 03:03PM	Teva Pharmaceutical Industries (TEVA): Among the Top Healthcare Stocks to Buy According to Billionaire David Einhorn (Insider Monkey)
Apr-10-25 07:46PM	Analyst Report: Teva Pharmaceutical Industries Limited (Morningstar Research) -9.46%
Apr-09-25 03:59PM	Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out (Seeking Alpha)
Apr-08-25 09:35AM	Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory (Insider Monkey)
Apr-07-25 08:00AM	Teva and Samsung Bioepis Announce Biosimilar EPYSQLI (eculizumab-aagh) Injection Now Available in the United States (GlobeNewswire)
07:30AM	Teva Announces FDA Filing Acceptance for AJOVY (fremanezumab) in Pediatric Episodic Migraine Prevention (GlobeNewswire)
Apr-04-25 11:10PM	Arcutis Biotherapeutics: Zoryve's Growth Impresses, But Valuation Is A Concern (Rating Upgrade) (Seeking Alpha) -7.07%
Apr-03-25 04:35PM	Top Stock Reports for Cisco, Caterpillar & CME (Zacks)
02:19PM	Analyst Report: Teva Pharmaceutical Industries Limited (Morningstar Research)
Apr-02-25 01:06PM	TCW Relative Value Mid Cap Fund Q4 2024 Commentary (Seeking Alpha)
Apr-01-25 01:05PM	Teva announces presentation of survey study on TEV-749 (TipRanks)
10:02AM	Is Teva Pharmaceutical Industries (TEVA) the Most Undervalued Healthcare Stock to Buy According to Analysts? (Insider Monkey)
Mar-31-25 01:00PM	New Data Strengthens Teva's Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable (GlobeNewswire)
Mar-30-25 05:00AM	Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors (Seeking Alpha)
Mar-28-25 09:44AM	AbbVie Vs. Sanofi: Which Is The Better Investment Right Now (Seeking Alpha)
06:11AM	These Are My 3 Worst-Performing Stocks So Far in 2025 -- and the One I'm Buying More of Now (Motley Fool)
Mar-27-25 04:30PM	Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025 (GlobeNewswire)
04:30PM	Teva Releases Q1 2025 Aide Memoire (GlobeNewswire)
Mar-24-25 05:06AM	Billionaire Stanley Druckenmiller Jettisoned Shares of Palantir and Nvidia, and Is Piling Into 3 High-Profile Turnaround Stocks (Motley Fool)
Mar-22-25 05:20PM	Was Jim Cramer Right About Teva Pharmaceutical Industries (TEVA)? (InsiderMonkey)
Mar-21-25 07:21AM	Merck Vs. Bristol-Myers Squibb: Which Pharma Stock Should You Buy (SeekingAlpha)
Mar-19-25 07:00AM	Here Are Billionaire Stanley Druckenmiller's 5 Biggest Stock Holdings (Fool)
Mar-18-25 03:22PM	Teva Pharmaceutical Stock Scores RS Rating Upgrade (Investor's Business Daily)
Mar-14-25 03:27AM	Teva Upgrades Its 4PL Model, Enhancing Medicine Accessibility for Patients with Kerry Pharma (PR Newswire)
Mar-11-25 07:08AM	Teva debuts global campaign encouraging people to get outside (Retail Dive) +9.75%
Mar-03-25 04:30PM	Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March (GlobeNewswire)
Mar-01-25 05:04PM	Why Axsome Therapeutics, Inc. (AXSM) is Skyrocketing So Far in 2025 (Insider Monkey)
02:52PM	Is Teva Pharmaceuticals Industries Limited (TEVA) the Best Weight Loss Drug Stock to Buy According to Analysts? (Insider Monkey)
Feb-28-25 02:11AM	Teva targets schizophrenia to build on innovative medicines growth (Pharma Voice)
Feb-27-25 08:34AM	Is Teva Pharmaceutical Industries Limited (TEVA) the Best Low Price Pharma Stock to Invest In Right Now? (Insider Monkey)
08:00AM	2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, and Texas, Funded by Teva Pharmaceuticals (GlobeNewswire)
Feb-25-25 05:03PM	Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder (Business Wire)
04:00PM	Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder (GlobeNewswire)
02:06PM	Teva Pharmaceutical Industries Limited (TEVA): Among Bourgeon Capitals Top Stock Picks (Insider Monkey)
Feb-24-25 08:22AM	Sanofi/Teva Unveil New Detailed Data For Duvakitug Study Supporting Overall Efficacy For Common Inflammatory Bowel Disease (Benzinga)
06:38AM	Teva and Alvotech launch ustekinumab biosimilar injection in US (Pharmaceutical Technology)
06:19AM	Sanofi, Teva add to case for new bowel disease drug (BioPharma Dive)
05:23AM	Sanofi and Teva report new outcomes from Phase IIb trial of duvakitug (Clinical Trials Arena)
Feb-22-25 02:20AM	Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn's Disease (GlobeNewswire)
Feb-21-25 06:00AM	Teva and Alvotech Announce SELARSDI (ustekinumab-aekn) Injection Now Available in the U.S. (GlobeNewswire)
Feb-20-25 05:06AM	Billionaire Stanley Druckenmiller Dumped Duquesne's Entire Stake in Broadcom and Bought One of Wall Street's Hottest Drug Stocks Hand Over Fist (Motley Fool)
Feb-19-25 08:28AM	Is Teva Pharmaceutical (TEVA) Trading at a Discount? (Insider Monkey)
Feb-18-25 04:30PM	Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn's and Colitis Organisation (ECCO) (GlobeNewswire)
11:27AM	FDA To Review Teva and Alvotech Drug That Could Compete With Regeneron's Eylea (Investopedia)
06:00AM	Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea (aflibercept) (GlobeNewswire)
Feb-14-25 06:32PM	Stanley Druckenmiller's Strategic Moves: A Closer Look at Teva Pharmaceutical Industries Ltd (GuruFocus.com)
Feb-10-25 12:33PM	Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025' (Benzinga)
06:45AM	Axsome secures top drugs future with Teva patent settlement (BioPharma Dive)
Jan-31-25 08:00AM	This Drug Stock Sits On A Strong Earnings Foundation As It Tests New Entry (Investor's Business Daily)
02:14AM	Teva Pharmaceutical Industries Ltd (TEVA) Q4 2024 Earnings Call Highlights: Strong Revenue ... (GuruFocus.com)
Jan-30-25 07:05AM	Why Teva Pharmaceuticals (TEVA) Crashed on Wednesday? (Insider Monkey)
Jan-29-25 03:37PM	Analyst Report: Teva Pharmaceutical Industries Limited (Morningstar Research) -13.89%
02:26PM	Why Teva Pharmaceutical Stock Is Sinking Today (Motley Fool)
02:15PM	Teva Pharmaceutical Industries (TEVA) Q4 2024 Earnings Call Transcript (Motley Fool)
01:18PM	Teva Stock Dives 14%. Why Its CEO Says It's A Victim. (Investor's Business Daily)
01:18PM	Teva Stock Dives 14%. 'We're Victims Of Our Own Success,' Says CEO. (Investor's Business Daily)
12:43PM	Trump Media's Truth.Fi, T-Mobile, Teva: Market Minute (Yahoo Finance Video)
11:39AM	VF Corp, Corning, Teva: Trending stocks (Yahoo Finance Video)
09:32AM	Teva Pharmaceutical Posts Lower Revenue. Stock Slips. (Investor's Business Daily)
09:30AM	Teva Pharmaceutical Industries (TEVA) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
07:00AM	Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth (GlobeNewswire)

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: United States, Europe, and International Markets. The United States segment focuses on therapeutic area of central nervous system (CNS) portfolio, and is involved in the distribution business of generic, biosimilar and medicines, and over-the-counter (OTC) pharmaceutical products from the firm and third-party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals, and physician offices in the United States. The Europe segment offers OTC portfolio including SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brands in European Union, the United Kingdom, and certain other European countries. The International Markets segment provides its products to countries such as Canada, Israel, Russia, Latin America, and Japan. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sabag Mark	See "Remarks"	May 08 '25	Sale	18.04	337,915	6,097,304	150,996	May 12 04:00 PM
Sabag Mark	Officer	May 08 '25	Proposed Sale	18.04	337,915	6,097,324		May 08 02:34 PM
Daniell Richard	Exec. VP, European Commercial	Mar 05 '25	Sale	15.91	70,961	1,128,642	48,384	Mar 07 04:05 PM
Hughes Eric A	See "Remarks"	Mar 04 '25	Sale	15.73	15,174	238,757	8,077	Mar 06 04:11 PM
Hughes Eric A	See "Remarks"	Mar 05 '25	Sale	15.91	8,077	128,531	0	Mar 06 04:11 PM
Daniell Richard	Exec. VP, European Commercial	Mar 04 '25	Sale	15.73	91,608	1,441,415	7,108	Mar 06 04:06 PM
Daniell Richard	Exec. VP, European Commercial	Mar 05 '25	Sale	15.91	48,764	775,991	0	Mar 06 04:06 PM
Francis Richard D	President and CEO	Mar 04 '25	Sale	15.73	15,514	244,107	280,042	Mar 06 04:03 PM
Francis Richard D	President and CEO	Mar 05 '25	Sale	15.91	8,259	131,427	271,783	Mar 06 04:03 PM
Daniell Richard	Officer	Mar 05 '25	Proposed Sale	15.83	70,961	1,123,585		Mar 05 04:29 PM
Daniell Richard	Exec. VP, European Commercial	Mar 03 '25	Sale	16.19	49,314	798,172	12,936	Mar 05 04:12 PM
Daniell Richard	Exec. VP, European Commercial	Mar 04 '25	Sale	15.56	12,936	201,253	0	Mar 05 04:12 PM
Hughes Eric A	See "Remarks"	Mar 03 '25	Sale	16.19	19,726	319,275	5,174	Mar 05 04:08 PM
Hughes Eric A	See "Remarks"	Mar 04 '25	Sale	15.56	5,174	80,495	0	Mar 05 04:08 PM
Francis Richard D	President and CEO	Mar 03 '25	Sale	16.19	24,892	402,889	251,783	Mar 05 04:04 PM
Francis Richard D	President and CEO	Mar 04 '25	Sale	15.56	6,450	100,347	245,333	Mar 05 04:04 PM
Fox Christine	Officer	Mar 04 '25	Proposed Sale	16.00	6,181	98,896		Mar 04 07:02 PM
McAvoy David R.	Officer	Mar 04 '25	Proposed Sale	16.00	4,827	77,232		Mar 04 06:57 PM
Hughes Eric A	Officer	Mar 04 '25	Proposed Sale	16.00	23,251	372,016		Mar 04 06:44 PM
Daniell Richard	Officer	Mar 04 '25	Proposed Sale	16.00	86,400	1,382,400		Mar 04 06:37 PM
Francis Richard D	Officer	Mar 04 '25	Proposed Sale	16.00	23,773	380,368		Mar 04 06:30 PM
Kalif Eliyahu Sharon	EVP, Chief Financial Officer	Feb 28 '25	Sale	16.21	55,750	903,462	147,941	Mar 04 04:02 PM
Francis Richard D	Officer	Mar 03 '25	Proposed Sale	16.46	31,342	515,889		Mar 03 01:14 PM
Hughes Eric A	Officer	Mar 03 '25	Proposed Sale	16.46	24,900	409,854		Mar 03 01:07 PM
Daniell Richard	Officer	Mar 03 '25	Proposed Sale	16.46	62,250	1,024,635		Mar 03 12:59 PM
Kalif Eliyahu Sharon	Officer	Feb 28 '25	Proposed Sale	16.21	55,750	903,463		Feb 28 11:52 AM
Francis Richard D	President and CEO	Feb 18 '25	Sale	16.95	75,506	1,279,661	209,444	Feb 19 04:03 PM
Francis Richard D	Officer	Feb 18 '25	Proposed Sale	16.95	75,506	1,279,661		Feb 18 12:38 PM
Sabag Mark	See "Remarks"	Feb 12 '25	Sale	16.25	177,626	2,886,565	204,964	Feb 14 04:03 PM
Sabag Mark	Officer	Feb 12 '25	Proposed Sale	16.25	177,626	2,886,555		Feb 13 08:06 AM
MIGNONE ROBERTO	Director	Dec 20 '24	Sale	22.01	286,000	6,294,031	695,000	Dec 26 04:02 PM
Bridger Management, LLC (1)	Shareholder	Dec 20 '24	Proposed Sale	21.31	286,000	6,094,660		Dec 20 07:03 PM
Fox Christine	EVP, Head of U.S. Commercial	Nov 20 '24	Sale	16.87	19,388	327,085	44,104	Nov 21 04:04 PM
Fox Christine	Officer	Nov 20 '24	Proposed Sale	16.87	19,388	327,085		Nov 20 11:39 AM
Daniell Richard	Exec. VP, European Commercial	Aug 12 '24	Sale	17.30	98,943	1,711,447	0	Aug 13 04:09 PM
Grant Angus	EVP, Business Development	Aug 09 '24	Sale	17.28	4,065	70,243	8,848	Aug 13 04:06 PM
Hughes Eric A	See "Remarks"	Aug 09 '24	Sale	17.38	45,060	782,972	0	Aug 13 04:02 PM
Daniell Richard	Officer	Aug 12 '24	Proposed Sale	17.30	98,943	1,711,444		Aug 12 04:09 PM
Hughes Eric A	Officer	Aug 09 '24	Proposed Sale	17.38	45,060	782,974		Aug 12 03:59 PM
Grant Angus	Officer	Aug 09 '24	Proposed Sale	17.28	4,065	70,243		Aug 09 03:59 PM
Hughes Eric A	See "Remarks"	Aug 01 '24	Sale	17.25	24,537	423,280	45,060	Aug 05 07:35 AM
Hughes Eric A	Officer	Aug 01 '24	Proposed Sale	17.25	24,537	423,281		Aug 01 04:00 PM
MIGNONE ROBERTO	Director	Jun 18 '24	Sale	17.03	519,000	8,838,570	981,000	Jun 21 04:05 PM
Weiss Amir	Chief Accounting Officer	May 16 '24	Sale	16.65	12,635	210,377	5,179	May 17 07:41 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Teva- Pharmaceutical Industries Ltd. ADR

Upgrade your FINVIZ experience